Headline News

 

Lilly’s Retevmo highlights substantial event free survival benefit as an adjuvant therapy in early stage RET fusion-positive lung cancer

Posted on February 16, 2026

Lilly’s Retevmo highlights substantial event-free survival benefit as an adjuvant therapy in early stage RET fusion-positive lung cancer

Posted on February 16, 2026

Astrazeneca releases new positive meaningful results from the phase III KALOS and LOGOS trials for Breztri in patients with uncontrolled asthma

Posted on February 16, 2026

Sanofi’s Beyfortus study highlights benefit for infants beyond first RSV season

Posted on February 16, 2026

Sanofi officially completed the acquisition of Dynavax

Posted on February 16, 2026

Novo Nordisk takes legal action against Hims & Hers to protect patients from knock off Wegovy

Posted on February 10, 2026

Update on Saphnelo subcutaneous administration in systemic lupus erythematosus

Posted on February 10, 2026

Datroway grants priority review for patients with metastatic triple negative breast cancer who are not candidates for immunotherapy

Posted on February 10, 2026

Pfizer’s ultra long acting injectable GLP-1 RA highlights continued weight loss in phase 2b trial

Posted on February 10, 2026

Pfizer launches new cost savings program on TrumpRx to lower drug costs for Americans

Posted on February 10, 2026

HYMPAVZI granted priority review for the treatment of two Hemophilia A or B patient populations

Posted on February 10, 2026

Rilzabrutinib designated breakthrough therapy and orphan drug in the U.S and Japan for the treatment of warm autoimmune hemolytic anemia

Posted on February 10, 2026

GSK’s Nucala approved by the European Commission for the treatment of chronic obstructive pulmonary disease

Posted on February 10, 2026

GSK’s RSV vaccine Arexvy is accepted for regulatory review in China

Posted on February 10, 2026

Lilly set to acquire Orna Therapeutics

Posted on February 10, 2026